A Comprehensive Multicenter Clinical Evaluation of Xeligekimab in the Treatment of Moderate-to-Severe Psoriasis (ChiCTR) - Jan 31, 2026 - P=N/A | N=200 | Not yet recruiting | Sponsor: Chongqing Hospital of Traditional Chinese Medicine; Chongqing Hospital of Traditional Chinese Medicine
New trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis
|